乳腺癌根治术后应用紫杉醇脂质体行辅助化疗的临床观察

Clinical observation of Paclitaxel Liposome in adjuvant chemotherapy after breast cancer radical mastectomy

目的评价乳腺癌根治术后应用紫杉醇脂质体与传统紫杉醇化疗的临床近期疗效和不良反应的差别。方法将76例乳腺癌根治术后患者随机分成两组,试验组45例,对照组31例。试验组应用紫杉醇脂质体(135mg/m2)进行化疗,对照组应用传统紫杉醇(135mg/m2)进行化疗。结果 76例患者均可评价疗效,全组患者中完全缓解(CR)6例,占7.8%;部分缓解(PR)21例,占21%,总有效率35.5%。主要不良反应为骨髓抑制、消化道症状、脱发、肌肉关节酸痛等,无严重超敏反应,试验组过敏反应较对照组明显减低(P<0.05)。结论对于复治患者,紫杉醇脂质体有效率较传统紫杉醇药物高,而且紫杉醇脂质体出现过敏反应者明显减少。

Objective To evaluate the difference of clinical short-term effect and adverse reactions between Paclitaxel Liposome and Paclitaxel after breast cancer radical mastectomy. Methods 76 patients after radical mastectomy were randomly divided into two groups, the experimental group included 45 cases which used the Paclitaxel Liposome (135mg/m2) in chemotherapy, and 31 cases in control group with Paclitaxel (135mg/m2)in chemotherapy. Results All patients were evaluable, 6 cases(7.8%) were CR, 21 cases(21%) were PR, the total effective rate were 35.5%. The main adverse reactions include marrow suppression, gastrointestinal symptoms, hair loss, muscle and joint painetc. There is no serious hypersensitivity. The rate of allergic reactions in experimental group was significantly lower than that in the control group. Conclusion To retreate patients, the rate of curative effect in Paclitaxel Liposome group is higher than the Paclitaxel group, and the rate of allergic reactions is significantly lower in Paclitaxel Liposome group.